These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1347 related items for PubMed ID: 26958938

  • 1. Bufalin suppresses hepatocellular carcinoma invasion and metastasis by targeting HIF-1α via the PI3K/AKT/mTOR pathway.
    Wang H, Zhang C, Xu L, Zang K, Ning Z, Jiang F, Chi H, Zhu X, Meng Z.
    Oncotarget; 2016 Apr 12; 7(15):20193-208. PubMed ID: 26958938
    [Abstract] [Full Text] [Related]

  • 2. Activation of PI3 kinase/Akt/HIF-1α pathway contributes to hypoxia-induced epithelial-mesenchymal transition and chemoresistance in hepatocellular carcinoma.
    Jiao M, Nan KJ.
    Int J Oncol; 2012 Feb 12; 40(2):461-8. PubMed ID: 21922131
    [Abstract] [Full Text] [Related]

  • 3. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.
    Zhang DM, Liu JS, Deng LJ, Chen MF, Yiu A, Cao HH, Tian HY, Fung KP, Kurihara H, Pan JX, Ye WC.
    Carcinogenesis; 2013 Jun 12; 34(6):1331-42. PubMed ID: 23393227
    [Abstract] [Full Text] [Related]

  • 4. Bufalin inhibits ovarian carcinoma via targeting mTOR/HIF-α pathway.
    Su S, Dou H, Wang Z, Zhang Q.
    Basic Clin Pharmacol Toxicol; 2021 Feb 12; 128(2):224-233. PubMed ID: 32905663
    [Abstract] [Full Text] [Related]

  • 5. Rhapontigenin inhibits TGF-β-mediated epithelial‑mesenchymal transition via the PI3K/AKT/mTOR pathway and is not associated with HIF-1α degradation.
    Yeh YH, Wang SW, Yeh YC, Hsiao HF, Li TK.
    Oncol Rep; 2016 May 12; 35(5):2887-95. PubMed ID: 26986649
    [Abstract] [Full Text] [Related]

  • 6. Effect of PI3K/AKT/mTOR Signaling Pathway on Regulating and Controlling the Anti-Invasion and Metastasis of Hepatoma Cells by Bufalin.
    Sheng X, Zhu P, Zhao Y, Zhang J, Li H, Zhao H, Qin J.
    Recent Pat Anticancer Drug Discov; 2021 May 12; 16(1):54-65. PubMed ID: 33530915
    [Abstract] [Full Text] [Related]

  • 7. Ruscogenin suppressed the hepatocellular carcinoma metastasis via PI3K/Akt/mTOR signaling pathway.
    Hua H, Zhu Y, Song YH.
    Biomed Pharmacother; 2018 May 12; 101():115-122. PubMed ID: 29477471
    [Abstract] [Full Text] [Related]

  • 8. Canagliflozin Modulates Hypoxia-Induced Metastasis, Angiogenesis and Glycolysis by Decreasing HIF-1α Protein Synthesis via AKT/mTOR Pathway.
    Luo J, Sun P, Zhang X, Lin G, Xin Q, Niu Y, Chen Y, Xu N, Zhang Y, Xie W.
    Int J Mol Sci; 2021 Dec 11; 22(24):. PubMed ID: 34948132
    [Abstract] [Full Text] [Related]

  • 9. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
    Jung KH, Choi MJ, Hong S, Lee H, Hong SW, Zheng HM, Lee HS, Hong S, Hong SS.
    Cancer Lett; 2012 Mar 28; 316(2):187-95. PubMed ID: 22182943
    [Abstract] [Full Text] [Related]

  • 10. STYK1 promotes epithelial-mesenchymal transition and tumor metastasis in human hepatocellular carcinoma through MEK/ERK and PI3K/AKT signaling.
    Wang Z, Qu L, Deng B, Sun X, Wu S, Liao J, Fan J, Peng Z.
    Sci Rep; 2016 Sep 15; 6():33205. PubMed ID: 27628214
    [Abstract] [Full Text] [Related]

  • 11. Dictamnine promotes apoptosis and inhibits epithelial-mesenchymal transition, migration, invasion and proliferation by downregulating the HIF-1α and Slug signaling pathways.
    Wang JY, Wang Z, Li MY, Zhang Z, Mi C, Zuo HX, Xing Y, Wu YL, Lian LH, Xu GH, Piao LX, Ma J, Jin X.
    Chem Biol Interact; 2018 Dec 25; 296():134-144. PubMed ID: 30266538
    [Abstract] [Full Text] [Related]

  • 12. Sanguinarine inhibits epithelial-mesenchymal transition via targeting HIF-1α/TGF-β feed-forward loop in hepatocellular carcinoma.
    Su Q, Fan M, Wang J, Ullah A, Ghauri MA, Dai B, Zhan Y, Zhang D, Zhang Y.
    Cell Death Dis; 2019 Dec 09; 10(12):939. PubMed ID: 31819036
    [Abstract] [Full Text] [Related]

  • 13. Combining combretastatin A4 phosphate with ginsenoside Rd synergistically inhibited hepatocellular carcinoma by reducing HIF-1α via PI3K/AKT/mTOR signalling pathway.
    Yang X, Gao M, Miao M, Jiang C, Zhang D, Yin Z, Ni Y, Chen J, Zhang J.
    J Pharm Pharmacol; 2021 Mar 04; 73(2):263-271. PubMed ID: 33793802
    [Abstract] [Full Text] [Related]

  • 14. Comprehensive anti-tumor effect of Brusatol through inhibition of cell viability and promotion of apoptosis caused by autophagy via the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
    Ye R, Dai N, He Q, Guo P, Xiang Y, Zhang Q, Hong Z, Zhang Q.
    Biomed Pharmacother; 2018 Sep 04; 105():962-973. PubMed ID: 30021391
    [Abstract] [Full Text] [Related]

  • 15. Plantamajoside inhibits the proliferation and epithelial-to-mesenchymal transition in hepatocellular carcinoma cells via modulating hypoxia-inducible factor-1α-dependent gene expression.
    Yin W, Xu J, Li C, Dai X, Wu T, Wen J.
    Cell Biol Int; 2020 Aug 04; 44(8):1616-1627. PubMed ID: 32239594
    [Abstract] [Full Text] [Related]

  • 16. Inflammatory interferon activates HIF-1α-mediated epithelial-to-mesenchymal transition via PI3K/AKT/mTOR pathway.
    Yeh YH, Hsiao HF, Yeh YC, Chen TW, Li TK.
    J Exp Clin Cancer Res; 2018 Mar 27; 37(1):70. PubMed ID: 29587825
    [Abstract] [Full Text] [Related]

  • 17. Ropivacaine suppresses tumor biological characteristics of human hepatocellular carcinoma via inhibiting IGF-1R/PI3K/AKT/mTOR signaling axis.
    Zhang R, Lian Y, Xie K, Cai Y, Pan Y, Zhu Y.
    Bioengineered; 2021 Dec 27; 12(2):9162-9173. PubMed ID: 34696683
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of PI3K/Akt/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells.
    Yang J, Pi C, Wang G.
    Biomed Pharmacother; 2018 Jul 27; 103():699-707. PubMed ID: 29680738
    [Abstract] [Full Text] [Related]

  • 19. Long noncoding RNA CPS1-IT1 suppresses the metastasis of hepatocellular carcinoma by regulating HIF-1α activity and inhibiting epithelial-mesenchymal transition.
    Wang TH, Yu CC, Lin YS, Chen TC, Yeh CT, Liang KH, Shieh TM, Chen CY, Hsueh C.
    Oncotarget; 2016 Jul 12; 7(28):43588-43603. PubMed ID: 27248828
    [Abstract] [Full Text] [Related]

  • 20. IPD-196, a novel phosphatidylinositol 3-kinase inhibitor with potent anticancer activity against hepatocellular carcinoma.
    Lee JH, Lee H, Yun SM, Jung KH, Jeong Y, Yan HH, Hong S, Hong SS.
    Cancer Lett; 2013 Feb 01; 329(1):99-108. PubMed ID: 23142281
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 68.